ELV Stock Forecast & Price Target

Elevance Health is positioned as a leading health insurer in the US, serving 45 million medical members with a diverse array of coverage plans, and demonstrating robust growth with a 10% year-over-year increase in OEP membership. The company's Medicare Advantage segment is projected to achieve a margin increase of over 150 basis points in 2026, supported by favorable pricing and an improved membership mix, particularly in D-SNPs, while the Medicaid margin exceeded prior guidance, reflecting positive adjustments in prior-period developments. Elevance's scale, strong local market share, and unique branding as the largest provider under Blue Cross Blue Shield, coupled with a solid external growth pipeline and increasing integration of services, contribute to a positive outlook for the company's financial performance.

Elevance Health's outlook is negatively impacted by guidance indicating a breakeven Medicaid margin for 2025, with a projected deterioration in margins for the second half of the year. The company faces several headwinds for 2026, including a significant decline in Medicaid membership and anticipated pressures in the commercial market, alongside challenges in controlling medical costs and achieving growth in government-sponsored programs. Additionally, the lowered earnings per share estimates for 2026, now at $25.54, reflect these ongoing issues, signaling potential difficulties in maintaining profitability amidst adverse regulatory changes and market conditions.